At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 83 target
Drug / intervention
Ruxolitinibdrug
Likely dose
Not stated in record
Key inclusion· 8
- ✓Pathologically confirmed T or NK cell lymphoma
- ✓Stage IB or greater for CTCL
- ✓Relapsed or refractory disease after at least 1 systemic therapy (except T-PLL, LGL, or T-cell lymphoproliferative diseases with JAK2 fusion)
- ✓Untreated patients may be allowed after discussion with PI
Key exclusion· 4
- ✕Uncontrolled concurrent illness including ongoing/active infection, uncontrolled diabetes, pneumonitis, congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness
- ✕Prior therapy with ruxolitinib
- ✕Receiving systemic therapy for another primary malignancy (other than T-cell lymphoma)
- ✕Positive serum ß-HCG pregnancy test in women of reproductive potential
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Multicenter Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib for Lymphoma. Currently recruiting, targeting 83 participants across 10 sites.
Detailed Summary
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK works along with another protein called STAT and is important for survival of many T or NK-cell lymphomas. By blocking JAK, ruxolitinib may cause T or NK-cell lymphomas to shrink.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
Timeline
Phase 2Recruiting
201720182019202020212022202320242025202620272028
Enrollment StartNov 2016
First PostedNov 2016
TodayJul 2026
Primary CompletionNov 2027
First PostedNov 28, 2016
Enrollment StartNov 1, 2016
Primary CompletionNov 1, 2027
TodayJul 2, 2026
Enrollment to primary: 11 yearsPosted 9.6 years agoPrimary completion in 1.3 years
Interventions
Ruxolitinibdrug